Compare NDAQ & IDXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NDAQ | IDXX |
|---|---|---|
| Founded | 1971 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9B | 45.4B |
| IPO Year | 2001 | 1996 |
| Metric | NDAQ | IDXX |
|---|---|---|
| Price | $93.71 | $518.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $105.62 | ★ $721.67 |
| AVG Volume (30 Days) | ★ 2.7M | 426.9K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 60.10 | 22.59 |
| EPS | 1.80 | ★ 7.74 |
| Revenue | $4,277,000,000.00 | ★ $4,303,702,000.00 |
| Revenue This Year | $10.52 | $10.88 |
| Revenue Next Year | $8.17 | $8.59 |
| P/E Ratio | ★ $52.53 | $66.33 |
| Revenue Growth | 7.87 | ★ 10.42 |
| 52 Week Low | $76.55 | $500.61 |
| 52 Week High | $101.79 | $769.98 |
| Indicator | NDAQ | IDXX |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 43.83 |
| Support Level | $93.19 | $500.61 |
| Resistance Level | $101.37 | $581.28 |
| Average True Range (ATR) | 2.17 | 11.20 |
| MACD | 0.13 | 1.64 |
| Stochastic Oscillator | 66.78 | 62.91 |
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.